Xtl Biopharmaceuticals (XTLB) Net Income Growth (3y) (2012 - 2024)

Xtl Biopharmaceuticals (XTLB) Net Income Growth (3y) (2012 - 2024) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income Growth (3y) (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - 9.16%
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 38.43%
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 13.80%
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -3.84%
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 79.26%
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Xtl Biopharmaceuticals 2.60 Bn 2.60 Bn - -

Historic Data

Download Data
DateValue
Dec 31, 2024 10.65%
Sep 30, 2024 16.98%
Jun 30, 2024 -32.45%
Mar 31, 2024 59.93%
Dec 31, 2023 -39.41%
Sep 30, 2023 87.96%
Jun 30, 2023 -18.82%
Mar 31, 2023 -94.10%
Dec 31, 2022 -2.15%
Sep 30, 2022 3.58%
Jun 30, 2022 -12.53%
Mar 31, 2022 65.62%
Dec 31, 2021 2.82%
Sep 30, 2021 7.51%
Jun 30, 2021 -121.80%
Mar 31, 2021 -31.33%
Dec 31, 2020 350.27%
Sep 30, 2020 -28.80%
Jun 30, 2020 46.13%
Mar 31, 2020 29.61%